Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

World-first gene therapy for cystic fibrosis targets lung stem cells?

21.10.2002


PhD student Maria Limberis inspects a CF mouse


The genetically – inherited disease cystic fibrosis causes severe, unrelenting lung disease in children and adults worldwide. Approximately 1 in 2,500 infants are born with this disease and only half survive past 30 years of age.

Now, researchers from the Women’s and Children’s Hospital, Adelaide have developed a novel system of gene therapy for lungs affected by cystic fibrosis, involving a natural compound found in our lungs which ’conditions’ lung airways to allow cells to take up the therapeutic gene.

Our lungs have developed highly effective ways to protect us from allergens, irritants, dust, viruses and other foreign particles. But according to principal medical scientist in Pulmonary Medicine, Dr David Parsons these defences also hinder effective gene therapy in our lungs.



"Using a mouse model of cystic fibrosis Maria Limberis, a PhD student in our lab, has helped us develop a system to briefly overcome these defences. As the cells lining the mouse nose behave in much the same way as human lung cells – this enables us to use the nose airways in mice to easily develop and test out gene therapy treatments.

"By instilling a single dose of a detergent found naturally in low amounts in our lungs, we are able to ’condition’ cells to take up the gene needed to treat cystic fibrosis.

" Viruses are very good at transferring their genetic material into cells and we make use of this by getting useful parts of an inactive and highly-modified human immunodeficiency virus type 1 (HIV 1) to safely transfer the cystic fibrosis gene into cells. We use this modified HIV because it is one of the few viruses that can give long-lasting gene transfer," Dr Parsons says.

Using this system, the research team has shown, for the first time in a living animal, that long-lived gene therapy for cystic fibrosis is possible. Not only do the airway cells take up the correcting gene, but these cells also show substantial recovery from the cystic fibrosis defect for, so far, at least 110 days.

"Airway cells are replaced every three months so our findings are particularly exciting because they imply we are in fact targeting airway stem cells through this approach - some of the therapeutic gene must have been passed on from these parent stem cells to their daughter cells for the effect to persist beyond three months," Dr Parsons says.

Research funding is now being sought to establish the most effective dose and timing for giving the detergent together with rigorous safety checks on the highly modified HIV-1 based virus particle used for the gene transfer.

Another senior member of the team, molecular biologist Dr Don Anson, explains, "Last year we published a method which vastly increases the safety with which HIV-1 can be modified and used to transfer genes without causing disease.

"We are now working to further improve on this method in order that patients and their families will feel totally confident to eventually take part in human trials of this gene therapy for cystic fibrosis," Dr Anson says.


The work from this research is to be published in Human Gene Therapy, volume 13 #16 on October 20.

Members of the Research Team are:
Dr David Parsons (Medical Scientist, Pulmonary Medicine)
Dr Don Anson (Senior Molecular Biologist, Chemical Pathology)
Dr Maria Fuller (Molecular Biologist, Chemical Pathology)
Ms Maria Limberis (PhD student, Pulmonary Medicine)

Dr Edna Bates | EurekAlert!
Further information:
http://www.wch.sa.gov.au/

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>